Research programme: MAPKAP K2 inhibitors - Astex Therapeutics

Drug Profile

Research programme: MAPKAP K2 inhibitors - Astex Therapeutics

Alternative Names: MAPKAP K2 inhibitors research programme - Astex Therapeutics

Latest Information Update: 31 May 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astex Therapeutics
  • Class
  • Mechanism of Action Mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation; Rheumatoid arthritis

Most Recent Events

  • 31 May 2006 No development reported - Preclinical for Inflammation in United Kingdom (unspecified route)
  • 31 May 2006 No development reported - Preclinical for Rheumatoid arthritis in United Kingdom (unspecified route)
  • 09 Aug 2005 Astex Technology Ltd is now called Astex Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top